Alethia Biotherapeutics Submits a Clinical Trial Application (CTA) for a Phase I Study with AB-16B5, an Inhibitor of EMT in Patients with Advanced Cancers
XL-protein and GENERIUM sign broad therapeutic license
Participating in the development of:
Type of medical product:
Fully humanized monoclonal antibody to VEGF
This is a Danish company and a World leader in the development of fully humanized therapeutic monoclonal antibodies.
© 2015, The International Biotechnology Center (IBC) “Generium”